Amenamevir is a novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2. Amenamenir stabilizes the interaction between the helicase-primase and its DNA substrates, preventing the progression through helicase or primase catalytic cycles, thus interfering with viral DNA replication and viral growth.
Amenamevir is a potent antiviral agent developed for treating herpes simplex virus (HSV) and varicella-zoster virus (VZV). Its core synthesis involves advanced organic chemistry to ensure high purity. The molecular formula is C14H18N4O2 with CAS number 1095678-43-5.
Strictly store in cool, dry conditions below 25°C. Handle with appropriate PPE to avoid inhalation or skin contact. Clinical use requires monitoring for potential renal toxicity and neurological side effects.